Page 9 - Poster Presentation News Today

ALEXANDRIA, Va., Nov. 17, 2022 /PRNewswire/ -- Congratulations to Kathryn DeStefano, Matthew Dickson, and Weston Schmutz, the recipients of AMCP F...

/PRNewswire/ -- Highlighting the companys industry leadership, Net Health Research and Clinical Outcomes was selected to give three presentations at the 99th...

- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

SUMMIT, N.J., Sept. 26, 2022 /PRNewswire/ -- CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studi...

AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy) AT-01 demonstrates

AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates...

Tenalisib (RP6530, selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial

Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation

Nobelpharma Will Also Have an Exhibit at the ConferenceBETHESDA, Md., Aug. 9, 2022 /PRNewswire/ -- Nobelpharma America, LLC, a pharmaceutical and ...